

General information about company

Scrip code	542650
NSE Symbol	METROPOLIS
MSEI Symbol	NOTLISTED
ISIN*	INE112L01020
Name of company	METROPOLIS HEALTHCARE LIMITED
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2019
Date of end of financial year	31-03-2020
Date of board meeting when results were approved	06-08-2019
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	30-07-2019
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Geographical
Description of single segment	
Start date and time of board meeting	06-08-2019 14:00
End date and time of board meeting	06-08-2019 18:00
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2019	30-06-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	15695.94	15695.94
	Other income	82.71	82.71
	Total income	15778.65	15778.65
2	Expenses		
(a)	Cost of materials consumed	3948.22	3948.22
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0

(d)	Employee benefit expense	3650.06	3650.06
(e)	Finance costs	145.73	145.73
(f)	Depreciation, depletion and amortisation expense	671.68	671.68
(f)	Other Expenses		
1	Other Expenses	3843.68	3843.68
2	Laboratory Testing Charges	135.91	135.91
10			
	Total other expenses	3979.59	3979.59
	Total expenses	12395.28	12395.28

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2019	30-06-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	3383.37	3383.37
4	Exceptional items	-686.48	-686.48
5	Total profit before tax	2696.89	2696.89
7	Tax expense		
8	Current tax	825.65	825.65
9	Deferred tax	39.27	39.27
10	Total tax expenses	864.92	864.92
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	1831.97	1831.97
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	1831.97	1831.97

Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2019	30-06-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		

1	Items that will not be reclassified subsequently to profit and loss (net of tax)	7.46	7.46
	Total Amount of items that will not be reclassified to profit and loss	7.46	7.46
2	Income tax relating to items that will not be reclassified to profit or loss	0	0
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	7.46	7.46

Financial Results – Ind-AS

Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2019	30-06-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	1839.43	1839.43
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	1003.57	1003.57
	Face value of equity share capital	2	2
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	3.65	3.65
	Diluted earnings (loss) per share from continuing operations	3.64	3.64
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	3.65	3.65
	Diluted earnings (loss) per share from continuing and discontinued operations	3.64	3.64

30	Debt equity ratio	0	0
31	Debt service coverage ratio	0	0
32	Interest service coverage ratio	0	0
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)	<p>1. These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.</p> <p>2. Metropolis Healthcare Limited (the 'Company') is engaged in the business of providing healthcare facilities. The principal activities of the Company consist of providing pathology and related healthcare services.</p> <p>3. The above unaudited results were reviewed by the Audit Committee at their meeting held on 6 August 2019 and thereafter approved by the Board of Directors at their meeting held on 6 August 2019. The statutory auditors have expressed an unmodified review opinion.</p> <p>4. The Company has adopted Ind AS -116 'Leases', effective annual reporting period beginning from 1 April 2019 and applied the Standard to its leases, retrospectively, with the cumulative effect of initially applying the Standard, recognised on the date of initial application (1 April 2019). Accordingly, the Company has not restated comparative information, instead, the cumulative effect of initially applying this Standard has been recognised as an adjustment to the opening balance of retained earnings as on 1 April 2019. This has resulted in recognising a Right of Use assets (ROU) of Rs 3,867.69 lakhs and a corresponding lease liability of Rs. 4,233.66 lakhs by adjusting retained earnings net of deferred taxes of Rs 238.09 lakhs. In the Statement of profit and loss for the current quarter, the nature of expenses in respect of operating leases has changed from lease rent in previous quarters/year to depreciation costs for the right of use assets and finance costs for interest accrued on lease liability.</p> <p>5. Disclosure of segment –wise information is not applicable, as pathology services is the Company's only business segment.</p> <p>6. The company completed an Initial Public Offer through an offer for sale by the selling shareholders of 1,36,85,095 equity shares of Rs.2 each at price of Rs. 880. The equity shares of the Company got listed on the BSE Limited and National Stock Exchange of India Limited on 15 April 2019. Expenses related to the offer are being borne by selling shareholders.</p> <p>7. The financial results for the quarter ended 31 March 2019 and 30 June 2018 were not subjected to limited review by the Statutory auditors of the Company and are as prepared by the Company's management. The figures for the quarter ended 31 March 2019 as reported in this financials results are the balancing figures between the audited figures in respect of full financial year and the year-to-date figures upto third quarter ended 31 December 2018, as prepared by the management and have not been subject to audit or review.</p> <p>8. Exceptional items in the consolidated financial results for the quarter ended 30 June 2019 includes: -</p> <p>a) provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS) aggregating to Rs.336.48 Lakhs and;</p> <p>b) provision for Rs.350.00 Lakhs on account of certain old unreconciled balances</p>
------------------------	--

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2019	01-04-2019
Date of end of reporting period	30-06-2019	30-06-2019
Whether accounts are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone

1	Segment Revenue (Income)		
	(net sale/income from each segment should be disclosed)		
	Total Segment Revenue		
	Less: Inter segment revenue	0	0
	Revenue from operations	0	0
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from each segment		
	Total Profit before tax		
	i. Finance cost		
	ii. Other Unallocable Expenditure net off Unallocable income		
	Profit before tax		
3	(Segment Asset - Segment Liabilities)		
	Segment Asset		
	Total Segment Asset		
	Un-allocable Assets		
	Net Segment Asset		
4	Segment Liabilities		
	Segment Liabilities		
	Total Segment Liabilities		
	Un-allocable Liabilities		
	Net Segment Liabilities		
	Disclosure of notes on segments		